NKTR
Nektar Therapeutics · Healthcare
Chief R&D Officer Jonathan Zalevsky sold $398K of Nektar Therapeutics
Sold$397,670
$70.00Price
5,681Shares
−37%Stake
What NKTR did after the filing
- The stock from Mon, Jul 6 open, $70.05
- +5.1%
- S&P 500, same days
- +2.5%
Measured over 30 trading days, to the Aug 18 close.
Traded Tue, Jun 30. Filed Thu, Jul 2, 7:06 PM ET, after the close. Returns use the Jul 6 open and the Aug 18 close. Not investment advice.